
LB PHARMACEUTICALS INC — Investor Relations & Filings
LB Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neuropsychiatric diseases, with a primary emphasis on schizophrenia and bipolar depression. The company's pipeline is centered on its lead product candidate, LB-102, an oral small molecule. LB-102 is being developed as a potential first-in-class benzamide antipsychotic for approval in the United States. The company is advancing LB-102 through late-stage clinical development, including a Phase III trial for schizophrenia and a Phase II study for bipolar depression, to address significant unmet needs in mental healthcare.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 424B3 - LB PHARMACEUTICALS INC (0001691082) (Filer) | 2026-05-12 | English | |
| 10-Q - LB PHARMACEUTICALS INC (0001691082) (Filer) | 2026-05-12 | English | |
| 8-K - LB PHARMACEUTICALS INC (0001691082) (Filer) | 2026-05-12 | English | |
| DEF 14A - LB PHARMACEUTICALS INC (0001691082) (Filer) | 2026-04-23 | English | |
| 424B3 - LB PHARMACEUTICALS INC (0001691082) (Filer) | 2026-04-14 | English | |
| S-1 - LB PHARMACEUTICALS INC (0001691082) (Filer) | 2026-04-06 | English |
Browse filings by year
9 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
11 filings
| |||||
| 45341733 | 424B3 - LB PHARMACEUTICALS INC (0001691082) (Filer) | 2026-05-12 | English | ||
| 45339969 | 10-Q - LB PHARMACEUTICALS INC (0001691082) (Filer) | 2026-05-12 | English | ||
| 45339545 | 8-K - LB PHARMACEUTICALS INC (0001691082) (Filer) | 2026-05-12 | English | ||
| 35871800 | DEF 14A - LB PHARMACEUTICALS INC (0001691082) (Filer) | 2026-04-23 | English | ||
| 34524397 | 424B3 - LB PHARMACEUTICALS INC (0001691082) (Filer) | 2026-04-14 | English | ||
| 33640225 | S-1 - LB PHARMACEUTICALS INC (0001691082) (Filer) | 2026-04-06 | English | ||
| 33052491 | S-8 - LB PHARMACEUTICALS INC (0001691082) (Filer) | 2026-03-26 | English | ||
| 31325131 | 4 Filing | 2026-02-10 | English | ||
| 31325124 | SCHEDULE 13D/A Filing | 2026-02-10 | English | ||
| 31325135 | 8-K Filing | 2026-02-05 | English | ||
| 31325132 | SCHEDULE 13G/A Filing | 2026-01-21 | English | ||
|
2025
4 filings
| |||||
| 12997415 | Major Shareholding Notification 2025 | 2025-12-31 | English | ||
| 12997416 | Director's Dealing 2025 | 2025-12-11 | English | ||
| 12997417 | Director's Dealing 2025 | 2025-11-19 | English | ||
| 12997418 | 8-K | 2025-11-13 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Amylyx Pharmaceuticals, Inc.
Develops therapies for neurodegenerative diseases and other…
|
AMLX | US | Manufacturing |
|
AN2 Therapeutics, Inc.
Biopharmaceutical firm developing boron-based drugs for inf…
|
ANTX | US | Manufacturing |
|
Ananda Pharma Plc
Biopharmaceutical firm developing cannabinoid-based medicin…
|
ANAN | GB | Manufacturing |
|
ANATOLİA TANI VE BİYOTEKNOLOJİ ÜRÜNLERİ ARAŞTIRMA GELİŞTİRME SANAYİ VE TİCARET A.Ş.
Designs, develops, and manufactures molecular diagnostic so…
|
ANGEN | TR | Manufacturing |
|
ANAVEX LIFE SCIENCES CORP.
Clinical-stage biopharmaceutical company developing therape…
|
AVXL | US | Manufacturing |
|
Anbio Biotechnology
Develops and provides in-vitro diagnostic (IVD) solutions a…
|
NNNN | KY | Manufacturing |
|
Anebulo Pharmaceuticals, Inc.
Clinical-stage biotech developing therapies for acute canna…
|
ANEB | US | Manufacturing |
|
AnGes, Inc.
Biopharmaceutical firm developing gene-based and nucleotide…
|
4563 | JP | Manufacturing |
|
ANG Lifesciences India Limited
Develops and manufactures sterile dry powder and liquid inj…
|
540694 | IN | Manufacturing |
|
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.
Develops biopharmaceuticals, genetic engineering products, …
|
300009 | CN | Manufacturing |
LB PHARMACEUTICALS INC via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33183/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33183 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33183 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33183 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33183}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for LB PHARMACEUTICALS INC (id: 33183)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.